This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "CORE-001 Study - Final Results of Cretostimogene Grenadenorepvec + Pembro in BCG-Unresponsive, High-Risk NMIBC With Carcinoma In Situ"

13 views
June 13, 2024
0 Comments
Login to view comments. Click here to Login